Defitelio and Foscavir drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Defitelio and Foscavir. Common interactions include cholestasis among females and acute respiratory distress syndrome among males.

The phase IV clinical study analyzes what interactions people who take Defitelio and Foscavir have. It is created by eHealthMe based on reports of 25 people who take Defitelio and Foscavir from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jan, 25, 2023

25 people who take Defitelio and Foscavir together, and have interactions are studied.

What is Defitelio?

Defitelio has active ingredients of defibrotide sodium. eHealthMe is studying from 3,105 Defitelio users for its effectiveness, alternative drugs and more.

What is Foscavir?

Foscavir has active ingredients of foscarnet sodium. eHealthMe is studying from 1,548 Foscavir users for its effectiveness, alternative drugs and more.

Number of Defitelio and Foscavir reports submitted per year:

Common Defitelio and Foscavir drug interactions by gender *:

female:

Cholestasis
Drug ineffective
Hepatitis a
Intermenstrual bleeding
Pulmonary toxicity
Venoocclusive disease
Acute respiratory distress syndrome
Colitis
Death
Disease progression

male:

Acute respiratory distress syndrome
Graft versus host disease
Platelet count decreased
Renal impairment
Subarachnoid haemorrhage
Bone marrow failure
Staphylococcal sepsis
Pneumonia
Cerebral haemorrhage

Common Defitelio and Foscavir drug interactions by age *:

0-1:

n/a

2-9:

Acute respiratory distress syndrome
Colitis
Gastritis
Melaena
Overdose
Pericardial effusion

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Venoocclusive disease
Pneumonia
Bone marrow failure
Death
Disease progression
Graft versus host disease
Renal impairment
Acute respiratory distress syndrome
Cerebral haemorrhage
Cholestasis

60+:

Platelet count decreased
Subarachnoid haemorrhage
Staphylococcal sepsis

Common conditions people have *:

Venoocclusive Liver Disease (small veins in the liver are obstructed): 18 people, 72.00%
Fever: 9 people, 36.00%
Sepsis (a severe blood infection that can lead to organ failure and death): 7 people, 28.00%
Pulmonary Veno-Occlusive Disease (obstructive disease of the pulmonary veins): 7 people, 28.00%
Disease Recurrence: 7 people, 28.00%
Diarrhea: 7 people, 28.00%
Venoocclusive Disease (small veins in the liver are obstructed): 5 people, 20.00%
Cytomegalovirus Infection: 5 people, 20.00%
Staphylococcal Infection (an infection with staphylococcus bacteria): 2 people, 8.00%
Pneumonia: 2 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Defitelio and Foscavir?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.